Literature DB >> 16820097

Conditional expression of human 15-lipoxygenase-1 in mouse prostate induces prostatic intraepithelial neoplasia: the FLiMP mouse model.

Uddhav P Kelavkar1, Anil V Parwani, Scott B Shappell, W David Martin.   

Abstract

The incidence and mortality of prostate cancer (PCa) vary greatly in different geographic regions, for which lifestyle factors, such as dietary fat intake, have been implicated. Human 15-lipoxygenase-1 (h15-LO-1), which metabolizes polyunsaturated fatty acids, is a highly regulated, tissue-specific, lipid-peroxidating enzyme that functions in physiological membrane remodeling and in the pathogenesis of atherosclerosis, inflammation, and carcinogenesis. We have shown that aberrant overexpression of 15-LO-1 occurs in human PCa, particularly high-grade PCa, and in high-grade prostatic intraepithelial neoplasia (HGPIN), and that the murine orthologue is increased in SV40-based genetically engineered mouse (GEM) models of PCa, such as LADY and TRansgenic Adenocarcinoma of Mouse Prostate. To further define the role of 15-LO-1 in prostate carcinogenesis, we established a novel GEM model with targeted overexpression of h15-LO-1 in the prostate [human fifteen lipoxygenase-1 in mouse prostate (FLiMP)]. We used a Cre- mediated and a loxP-mediated recombination strategy to target h15-LO-1 specifically to the prostate of C57BL/6 mice. Wild-type (wt), FLiMP+/-, and FLiMP+/+ mice aged 7 to 21, 24 to 28, and 35 weeks were characterized by histopathology, immunohistochemistry (IHC), and DNA/RNA and enzyme analyses. Compared to wt mice, h15-LO-1 enzyme activity was increased similarly in both homozygous FLiMP+/+ and hemizygous FLiMP+/- prostates. Dorsolateral and ventral prostates of FLiMP mice showed focal and progressive epithelial hyperplasia with nuclear atypia, indicative of the definition of mouse prostatic intraepithelial neoplasia (mPIN) according to the National Cancer Institute. These foci showed increased proliferation by Ki-67 IHC. No progression to invasive PCa was noted up to 35 weeks. By IHC, h15-LO-1 expression was limited to luminal epithelial cells, with increased expression in mPIN foci (similar to human HGPIN). In summary, targeted overexpression of h15-LO-1 (a gene overexpressed in human PCa and HGPIN) to mouse prostate is sufficient to promote epithelial proliferation and mPIN development. These results support 15-LO-1 as having a role in prostate tumor initiation and as an early target for dietary or other prevention strategies. The FLiMP mouse model should also be useful in crosses with other GEM models to further define the combinations of molecular alterations necessary for PCa progression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16820097      PMCID: PMC1601466          DOI: 10.1593/neo.06202

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  67 in total

1.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras.

Authors:  E L Jackson; N Willis; K Mercer; R T Bronson; D Crowley; R Montoya; T Jacks; D A Tuveson
Journal:  Genes Dev       Date:  2001-12-15       Impact factor: 11.361

Review 2.  Autochthonous mouse models for prostate cancer: past, present and future.

Authors:  W J Huss; L A Maddison; N M Greenberg
Journal:  Semin Cancer Biol       Date:  2001-06       Impact factor: 15.707

3.  13-Hydroxyoctadecadienoic acid is the mitogenic signal for linoleic acid-dependent growth in rat hepatoma 7288CTC in vivo.

Authors:  L A Sauer; R T Dauchy; D E Blask; B J Armstrong; S Scalici
Journal:  Cancer Res       Date:  1999-09-15       Impact factor: 12.701

4.  The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model.

Authors:  P J Kaplan; S Mohan; P Cohen; B A Foster; N M Greenberg
Journal:  Cancer Res       Date:  1999-05-01       Impact factor: 12.701

5.  Epigenetic heterogeneity of high-grade prostatic intraepithelial neoplasia: clues for clonal progression in prostate carcinogenesis.

Authors:  Rui Henrique; Carmen Jerónimo; Manuel R Teixeira; Mohammad O Hoque; André L Carvalho; Irene Pais; Franclim R Ribeiro; Jorge Oliveira; Carlos Lopes; David Sidransky
Journal:  Mol Cancer Res       Date:  2006-01       Impact factor: 5.852

6.  Nkx3.1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases.

Authors:  Cory Abate-Shen; Whitney A Banach-Petrosky; Xiaohui Sun; Kyriakos D Economides; Nishita Desai; Jeffery P Gregg; Alexander D Borowsky; Robert D Cardiff; Michael M Shen
Journal:  Cancer Res       Date:  2003-07-15       Impact factor: 12.701

7.  Pten is essential for embryonic development and tumour suppression.

Authors:  A Di Cristofano; B Pesce; C Cordon-Cardo; P P Pandolfi
Journal:  Nat Genet       Date:  1998-08       Impact factor: 38.330

8.  15-lipoxygenase-1 expression upregulates and activates insulin-like growth factor-1 receptor in prostate cancer cells.

Authors:  Uddhav P Kelavkar; Cynthia Cohen
Journal:  Neoplasia       Date:  2004 Jan-Feb       Impact factor: 5.715

9.  Early onset of neoplasia in the prostate and skin of mice with tissue-specific deletion of Pten.

Authors:  Stéphanie A Backman; Danny Ghazarian; Kelvin So; Otto Sanchez; Kay-Uwe Wagner; Lothar Hennighausen; Akira Suzuki; Ming-Sound Tsao; William B Chapman; Vuk Stambolic; Tak W Mak
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-27       Impact factor: 11.205

Review 10.  Roles of the Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis.

Authors:  Michael M Shen; Cory Abate-Shen
Journal:  Dev Dyn       Date:  2003-12       Impact factor: 3.780

View more
  19 in total

1.  Acute bacterial inflammation of the mouse prostate.

Authors:  Bayli J Boehm; Sara A Colopy; Travis J Jerde; Christopher J Loftus; Wade Bushman
Journal:  Prostate       Date:  2011-06-16       Impact factor: 4.104

Review 2.  Emerging cellular functions of the lipid metabolizing enzyme 15-Lipoxygenase-1.

Authors:  Melis Çolakoğlu; Sinem Tunçer; Sreeparna Banerjee
Journal:  Cell Prolif       Date:  2018-07-30       Impact factor: 6.831

3.  Impact of prostate inflammation on lesion development in the POET3(+)Pten(+/-) mouse model of prostate carcinogenesis.

Authors:  Grant N Burcham; Gregory M Cresswell; Paul W Snyder; Long Chen; Xiaoqi Liu; Scott A Crist; Michael D Henry; Timothy L Ratliff
Journal:  Am J Pathol       Date:  2014-11-22       Impact factor: 4.307

Review 4.  Fish consumption and risk of gastrointestinal cancers: a meta-analysis of cohort studies.

Authors:  Xiao-Feng Yu; Jian Zou; Jie Dong
Journal:  World J Gastroenterol       Date:  2014-11-07       Impact factor: 5.742

Review 5.  Drug discovery in prostate cancer mouse models.

Authors:  Kenneth C Valkenburg; Kenneth J Pienta
Journal:  Expert Opin Drug Discov       Date:  2015-06-01       Impact factor: 6.098

6.  15-lipoxygenase-1 activates tumor suppressor p53 independent of enzymatic activity.

Authors:  Hong Zhu; Wayne Glasgow; Margaret D George; Kali Chrysovergis; Kenneth Olden; John D Roberts; Thomas Eling
Journal:  Int J Cancer       Date:  2008-12-15       Impact factor: 7.396

7.  Neoplasia: the second decade.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

Review 8.  Mammalian lipoxygenases and their biological relevance.

Authors:  Hartmut Kuhn; Swathi Banthiya; Klaus van Leyen
Journal:  Biochim Biophys Acta       Date:  2014-10-12

9.  15-lipoxygenase-1 production is lost in pancreatic cancer and overexpression of the gene inhibits tumor cell growth.

Authors:  René Hennig; Timo Kehl; Seema Noor; Xian-Zhong Ding; Sambasiva M Rao; Frank Bergmann; Gerhard Fürstenberger; Markus W Büchler; Helmut Friess; Peter Krieg; Thomas E Adrian
Journal:  Neoplasia       Date:  2007-11       Impact factor: 5.715

10.  Genetic variation in IL-16 miRNA target site and time to prostate cancer diagnosis in African-American men.

Authors:  L Hughes; K Ruth; T R Rebbeck; V N Giri
Journal:  Prostate Cancer Prostatic Dis       Date:  2013-09-24       Impact factor: 5.554

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.